Venture Life: US and self-care revolution opens the door to much bigger growth opportunity
Healthcare is moving out of the doctors surgery and into consumers own hands. Ageing populations, greater awareness of preventative medicine and a rising desire to remain healthier for longer are encouraging people to treat everyday ailments earlier and more proactively. At the same time, stretched hospital systems, improved products, e-commerce and increasingly sophisticated consumer brands are making self-care easier and more accessible than ever.
Step forward , which has just completed perhaps the most important transformation in its 16-year history.
Here FY26 revenues came in at £50.0m for the 17 months to May 2026, up an impressive 16% LFL, split 14.8% volume vs 1.2% price. Better still, its Power Brands climbed 17% to £46.7m (93% of group), underpinned by innovation (19 new product launches), higher marketing spend (9.4% sales vs 6.1% LY) and a 156% jump in online to £12.8m (25% of group).
Indeed after selling its CDMO operations together with UltraDEX and Dentyl, Venture Life has emerged as a capital-light consumer healthcare platform focused on womens intimate health, hormonal health, energy management and ear-care. Anchored by £11.5m of net cash, despite investing £17.1m ($23m) on its transformational (up to $28m) FemiClear/CUROXEN acquisition in June.
Which will provide #VLG with not only an established sales team and relationships with Walmart, Walgreens, CVS and Target. But also turnover of approx $14m this year (vs $11m) and infrastructure to cross-pollinate existing brands Balance Activ, Health&Her, Lift and Earol into the worlds largest consumer healthcare market.
Elsewhere FY’26 EBITDA leapt 27% to £7.9m, albeit margins fell to 15.7% (23.2% LY) as #VLG invested in growth and temporarily carried an under-utilised cost base following the disposals. CEO Jerry Randall commenting: the group has “extraordinary growth prospects” and is targeting “revenues of £300m within the next 5 years alongside an adjusted EBITDA margin of 25%”.
Looking ahead Cavendish are forecasting 12M FY27 turnover, adjusted EBITDA and EPS of £54.7m, £11.6m and 6.9p respectively. Thus putting the stock at 68p on attractive multiples of 6.5x EV/EBITDA and 9.9x PER. Cavendish have a 150p/share target price vs my 112p fair value.
Finally as a normal part of succession planning, long time CEO & founder Jerry Randall is set to hand over the reins to CFO Daniel Wells in Dec'26.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
